Posted by Michael Wonder on 11 Jul 2023
European Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
11 July 2023 - Approval is based on results from the Phase I/II NP30179 study, where Columvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma.
Roche announced today that the European Commission has granted conditional marketing authorisation for Columvi (glofitamab) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
